Preliminary study on involving field irradiation radiotherapy in neoadjuvant chemoradiotherapy for esophageal cancer
DONG Xiaohuan,LIU Jun,LI Hongxuan,CHENG Yan,LI Yue,YU Wen,CAI Xuwei,FU Xiaolong
DOI: https://doi.org/10.19401/j.cnki.1007-3639.2023.03.010
2023-01-01
Abstract:Background and purpose: The standard treatment for patients with locally advanced esophageal cancer is neoadjuvant chemoradiotherapy(NCRT) plus radical resection. However, the technical aspects for implementing this comprehensive treatment strategy differ, especially in the controversial definition of the radiotherapy target area in NCRT. This study aimed to analyze the feasibility of involving field irradiation(IFI) in NCRT for locally advanced esophageal cancer. Methods: Retrospective analysis of locally advanced esophageal squamous cell carcinoma patients receiving NCRT in Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine from July 2016 to May 2017 showed that the radiotherapy target of all patients was our recommended IFI. The radiotherapy plan was redesigned for the enrolled patients according to the two traditional target delineation of elective node irradiation(ENI) and primary subclinical lesion irradiation(SLI). The dosimetric parameters of the three groups and the dose differences of organ at risk(OAR), such as lungs, heart and spinal cord, were compared, and the relationship between IFI Recurrence pattern and radiation target volumes was analyzed. Results: A total of 26 patients were enrolled. The average target volume of IFI was(277±77) cm~3, which was significantly lower compared with ENI and SLI(P<0.05). IFI could significantly reduce relative volume fraction of lungs irradiated more than 5 and 20 Gy(V 5 and V 20 ), lungs average dose(D mean ), heart V 30 ,heart D mean and spinal cord maximum dose(D max )(P<0.05), compared with ENI. Lungs V 20 , lungs D mean , heart D mean and spinal cord D max decreased by 27.1%, 22.5%, 27.4% and 6.4% compared with ENI, and 24.1%, 22.0%, 24.8% and 5.7% compared with SLI, respectively. After 28 to 69 months of follow-up, 13 patients had recurrence and metastasis, of whom 7 patients had distant metastasis, 4 patients had recurrence in the irradiation field, and 1 patient had local recurrence in the irradiation field. The 3-year overall survival(OS) rate and disease-free survival(DFS) rate were 50.0% and 42.3%, respectively. Conclusion: IFI recommended by our institution is feasible to ensure clinical efficacy while significantly reducing the radiation dose of lungs, heart and spinal cord.